News

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

This Month in Review features the approval of trospium chloride capsules (Cobenfy) as well as other clinical trials in the psychiatry field.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

Bau explains the challenges of using MELD to determine liver transplant referrals and other complexities of the evaluation process.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.

Positive 120-day data from the phase 2a study of CNP-104 in PBC highlight its efficacy across multiple immunological and clinical measurements

Phentolamine ophthalmic solution 0.75% effectively reversed pharmacologically-induced pupil dilation in the MIRA-2 and MIRA-3 clinical trials.

In this episode, Tina Bhutani, MD, MAS, joins The Medical Sisterhood for a discussion about confronting imposter syndrome as a woman in medicine.

Compared to those without SLD, patients with MASLD, MetALD, and other combination etiology had a greater risk of developing liver and gastrointestinal cancers.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Individuals diagnosed with retinitis pigmentosa experienced an elevated risk of depressive disorder, compared with the general Korean population.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.

Alcohol intake frequency was linked to a greater risk of IgAN, while dietary exposures like cheese, cereal, and sushi were associated with a reduced risk.

To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.

Expert clinical consensus from the National Lipid Association finds ApoB testing is useful to stratify ASCVD risk more accurately than LDL-C.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

Crimaldi reviews key considerations for the diagnosis and management of bowel ischemia, diverticulitis, and small bowel obstructions in GI inpatients.

At the Family Heart Global Summit 2024, Bhatia spoke about the importance of universal Lp(a) screening over only targeted screening.

In this episode, John Giacona, PhD, PA-C, shares insights from the 2024 AHA Hypertension Scientific Sessions, focusing on primary aldosteronism and renal denervation.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

A large study shows no women were anemic in the first trimester of pregnancy, but more than 80% of the women were iron deficient by the third trimester.

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.